Gilead just bought a cancer-immunotherapy company for $12 billion – Markets Insider
Markets Insider |
Gilead just bought a cancer-immunotherapy company for $12 billion
Markets Insider Gilead, known for its HIV and hepatitis C drugs, has been growing a cash pile over the past few years since the approval of its hepatitis C drug in 2013, leading investors to speculate what company it might buy. Gilead's purchase of Kite is the first … Kite Soars on Sale to Gilead – Biotech Movers Gilead Makes Long-Awaited Splash With $12B Bet on Kite, Cell Therapy Gilead is buying Santa Monica biotech firm Kite Pharma for $11.9 billion |
